stockportfolio.pro
ARWR vs BAX
Arrowhead Pharmaceuticals, Inc. and Baxter International Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Baxter International Inc. (BAX) | |
|---|---|---|
| Market cap | $10.0B | $10.0B |
| Revenue (latest FY) | $829.45M | $11.24B |
| Net income (latest FY) | $-1.63M | $-957.00M |
| Revenue growth (5y CAGR) | 56.6% | -0.7% |
| Net margin | -0.2% | -8.5% |
| Return on equity | -0.3% | -15.6% |
| P/E ratio | — | — |
| Dividend yield | — | 1.0% |
| Profitable years (of last 10) | 1 | 7 |
| Positive free cash flow | Yes | Yes |
See the full ARWR vs BAX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ARWR's full financials → Open BAX's full financials →More comparisons
Frequently asked questions
Which is bigger, ARWR or BAX?
Baxter International Inc. is larger by market capitalization — $10.0B versus $10.0B.
Which grows faster, ARWR or BAX?
Over the last five fiscal years, Arrowhead Pharmaceuticals, Inc. grew revenue faster — 56.6%/yr versus -0.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
ARWR fundamentals → · BAX fundamentals → · All 1,500+ companies → · Free screener →